Ycanth (Cantharidin) Patent Expiration, LOE Window & CMS Spending
Ycanth (Cantharidin) by Verrica: FDA Orange Book LOE 2041-02-19, 0 AB generics, $1.7M 2024 CMS Part D & Medicaid spend, and $8,220 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Verrica |
| FDA Application & Pathway | N212905 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2041-02-19 |
| Orange Book Patents (*PED Extensions) | 4 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $1.7M |
| 2024 Medicare Part D Spend | $15K |
| 2024 Medicaid Spend | $1.7M |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($8,220 intro WAC) |